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Rationale: Resolution mechanisms are central in both the maintenance of homeostasis and the return to 
catabasis following tissue injury and/or infections. Amongst the pro-resolving mediators, the essential fatty 
acid-derived specialized pro-resolving lipid mediators (SPM) govern immune responses to limit disease 
severity. Notably, little is known about the relationship between the expression and activity of SPM 
pathways, circulating phagocyte function and disease severity in patients infected with novel severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to coronavirus disease 2019 (COVID-19). 
 
Objective: Herein, we investigated the link between circulating SPM concentrations and phagocyte 
activation status and function in COVID-19 patients (n=39) compared to healthy (n=12) and post-COVID-
19 (n=8) volunteers. 
 
Methods and Results: Lipid mediator profiling demonstrated that plasma SPM concentrations were 
upregulated in patients with mild COVID-19 and are downregulated in those with severe disease. SPM 
concentrations were correlated with both circulating phagocyte activation status and function. Perturbations 
in plasma SPM concentrations and phagocyte activation were retained after the resolution of COVID-19 
clinical symptoms. Treatment of patients with dexamethasone upregulated both the expression of SPM 
biosynthetic enzymes in circulating phagocytes and plasma concentration of these mediators. Furthermore, 
incubation of phagocytes from COVID-19 patients with SPM rectified their phenotype and function. This 
included a downregulation in the expression of activation markers, a decrease in the Tissue Factor and 
inflammatory cytokine expression, and an upregulation of bacterial phagocytosis. 
 
Conclusions: The present findings suggest that downregulation of systemic SPM concentrations is linked 
with both increased disease severity and dysregulated phagocyte function. They also identify the 
upregulation of these mediators by dexamethasone as a potential mechanism in host protective activities 
elicited by this drug in COVID-19 patients. Taken together, our findings elucidate a role for altered 
resolution mechanisms in the disruption of phagocyte responses and the propagation of systemic 
inflammation in COVID-19.  
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Nonstandard Abbreviations and Acronyms: 
 
AA   arachidonic acid 
CD   cluster of differentiation 
COVID-19  coronavirus disease 2019 
DHA   docosahexaenoic acid 
DPA   docosapentaenoic acid 
EPA   eicosapentaenoic acid 
IFN   interferon 
IL   interleukin 
LM   lipid mediator 
MCTR   maresin conjugates in tissue regeneration 
n-3   omega-3 
PCTR   protectin conjugates in tissue regeneration 
PD   protectins 
PLS-DA  partial least-squares discriminant analysis 
RvD   D-series resolvin 
RvE   E-series resolvin 
RvT   13-series resolvin 
SARS-CoV-2  severe acute respiratory syndrome coronavirus 2 
SPM   specialized pro-resolving mediators 






The inflammatory response is an essential protective mechanism that evolved to safeguard the host 
from invading pathogens and facilitate the restoration of tissue function through repair and regeneration of 
damaged tissues1-4. This finely tuned response becomes unravelled in disease, often resulting in 
disseminated inflammation. One such example is coronavirus disease 2019 (COVID-19) caused by the 
novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)5. Current evidence suggests that in 
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require hospitalization. However, in the remainder of cases, SARS-CoV-2 results in moderate to severe 
disease requiring hospitalization, with a subset of these patients becoming critically ill and requiring 
ventilation support.  
 
COVID-19 is characterized by a number of clinical presentations that in severe cases include 
pneumonia, acute respiratory distress syndrome and multiple organ failure5. This disseminated 
inflammatory response is thought to involve alveolar damage that can lead to cardiovascular complications 
and multi-organ failure. A significant body of effort has now gone into understanding the mechanisms 
underpinning this dysregulated systemic inflammatory response, since insights into these mechanisms may 
provide novel therapeutic leads for the treatment of hospitalized patients. This notion is underpinned by 
results obtained in the RECOVERY Trial, which demonstrated a significant reduction in mortality in 
critically ill patients treated with the anti-inflammatory corticosteroid dexamethasone6.  
 
Initial efforts into detailing these inflammatory mechanisms found a marked upregulation of 
circulating pro-inflammatory cytokines as well as an increased inflammatory phenotype of innate immune 
cells, primarily monocytes, in COVID-19 patients with severe disease7-12. This phenotype is reminiscent of 
the dysregulated resolution responses observed following infections by other viral and bacterial pathogens1-
4. These findings suggest that in addition to an increase in pro-inflammatory mediator production there may 
also be disruptions in resolution pathways in COVID-19 patients. 
 
 Resolution mechanisms are orchestrated by a number of endogenous autacoids that include the 
omega-3 fatty acid derived specialized pro-resolving lipid mediators (SPM)4, 13. These molecules are 
classified into four distinct families: lipoxins, resolvins, protectins and maresins, which are produced via 
the stereoselective conversion of essential fatty acids. SPM display both host-directed as well as anti-viral 
actions during viral infections. For example, the docosahexaenoic acid (DHA)-derived Resolvin (Rv)D1 
and its precursor 17-hydroxy-docosahexaenoic acid regulate B-cell response during H1N1 infections in 
mice by promoting an antibody class switch14. The Protectin (PD) family of mediators regulate viral 
propagation by inhibiting intracellular viral RNA transport mechanisms15. Similarly, the eicosapentaenoic 
acid (EPA)-derived RvE1 reduces effector T-cell and neutrophil-mediated propagation of inflammation 
during herpes simplex virus infections16. Furthermore, recent studies demonstrate that circulating 
concentrations of these mediators are linked with disease outcome in sepsis and in treatment responsiveness 
in humans with chronic inflammatory conditions such as rheumatoid arthritis17, 18. 
 
 Given the immunoregulatory actions of SPM and the potential diagnostic and prognostic value of 
measuring peripheral levels of these molecules, we sought to evaluate whether SPM pathways are altered 
in COVID-19 patients. We also investigated the impact that disruptions in these pathways may have on 
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RESULTS 
 
Altered peripheral blood LM profiles in COVID-19 pneumonia patients. 
 
In order to evaluate whether SPM concentrations are differentially regulated in COVID-19 patients 
we first assessed plasma lipid mediator (LM) profiles in hospitalized patients with COVID-19 (n=38) and 
compared these with LM profiles obtained from healthy volunteers with no clinical suggestion of COVID-
19 infection (n=12; see Supplemental Table I for clinical characteristics). Using liquid chromatography 
tandem mass spectrometry (LC-MS/MS), we identified LM from all four bioactive metabolomes in both 
hospitalized patients and healthy volunteers. We then assessed their relative levels using Partial Least 
Squares Discriminant analysis (PLS-DA), a dimensionality-reducing multivariate analysis that creates a 
linear regression model accounting for multicollinearity and identifies the relationship between samples 
based on LM concentrations. This demonstrated that LM profiles in hospitalized COVID-19 patients were 
different from those found in plasma from healthy volunteers, as illustrated by a separate clustering of LM 
profiles between the two groups (Figure 1A and Supplemental Table II). Assessment of Variable 
Importance in Projection (VIP) scores, which identify those mediators that contribute most to the observed 
separation between the two groups, showed that 19 mediators displayed a VIP score >1 (Figure 1A). 
Intriguingly, the majority of mediators found to be differentially regulated between COVID-19 patients and 
healthy volunteers belonged to the SPM family. This included an upregulation of SPM from the DHA, n-3 
docosapentaenoic acid (DPA), and EPA bioactive metabolomes in COVID-19 patients, such as DHA-
derived MCTR3, PCTR3, and RvD6, and n-3 DPA-derived RvD5n-3 DPA and PD1n-3 DPA.  
 
To obtain insights into potential changes in LM biosynthetic pathways in COVID-19 patients, we 
next performed a pathway analysis on mediators that displayed the greatest differences in concentrations 
between the two groups (i.e. VIP scores >1). This demonstrated an upregulation of 5-Lipoxygenase 
(ALOX5)–ALOX15 interaction products as highlighted by increases in RvD6, RvD5n-3 DPA and RvE4, and 
a decrease in cytochrome (CY)P450–ALOX5 interaction products evidenced by a downregulation in 15-
epi-LXB4 in COVID-19 patients when compared with healthy volunteers (Figure 1B). Together these 
findings provide evidence for altered LM, in particular SPM, levels in COVID-19 patients. 
 
Differential regulation of SPM biosynthetic enzymes and receptors in peripheral blood phagocytes from 
COVID-19 patients. 
 
Phagocytes play a central role in LM production19, 20. Having identified changes in plasma 
concentrations of mediators from both ALOX and COX biosynthetic pathways, we next investigated 
whether these enzymes were differentially expressed in peripheral blood phagocytes from patients with 
COVID-19 when compared with those from healthy volunteers. Flow cytometric analysis of peripheral 
blood neutrophils from patients with COVID-19 demonstrated a significant downregulation in the 
expression of all LM biosynthetic enzymes analysed (Figure 1C, Supplemental Figure I-A). On the other 
hand, in peripheral blood monocytes we observed an overall trend towards increased expression of these 
enzymes, which reached statistical significance for COX-2 in all three monocyte subsets and for ALOX15 
in non-classical monocytes (Figure 1D-F). Together these findings uncover a differential regulation in the 
expression of LM biosynthetic enzymes in circulating phagocytes from COVID-19 patients.  
 
 The biological actions of SPM are mediated by cognate G protein-coupled receptors (GPCR)21, 22. 
Thus, we next evaluated whether phagocytes from COVID-19 patients displayed altered expression of SPM 
receptors. Flow cytometric assessment of SPM receptors in peripheral blood neutrophils demonstrated a 
significant upregulation of GPR32 and GPR101 (Figure 1G). The former receptor mediates the protective 
actions of RvD1, 17R-RvD1, RvD3, 17R-RvD3, RvD5, 15-epi-LXA4 and LXA421, 22, whereas the latter is 
the cognate receptor for RvD5n-3 DPA23. GPR32 was upregulated in all three monocytes subsets, while 
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significant downregulation of GPR18, the RvD2 receptor24, as well as a trend towards the downregulation 
of PD1 receptor GPR3725 in intermediate monocytes and MaR1 receptor LGR626 in all three monocytes 
subsets (Figure 1H-J). Together, these findings lend support to the hypothesis that resolution mechanisms 
are altered in peripheral blood phagocytes from COVID-19 patients.  
 
Peripheral blood phagocytes from COVID-19 patients display an altered activation status and function. 
 
We next assessed whether these changes in SPM pathways were reflected in a dysregulation of 
circulating phagocyte activation status and function. For this purpose, we evaluated the expression of 
proteins linked with the activation status of circulating phagocytes. PLS-DA unveiled an overall shift in the 
activation status of all four phagocyte subsets evaluated, as demonstrated by a separation of healthy 
volunteer and COVID-19 patient clusters (Figure 2A-D). In all phagocyte subsets, this phenotypic shift was 
primarily driven by upregulation of the integrin Cluster of Differentiation (CD)11b (Figure 2A-D). 
Additionally, we observed a downregulation in the expression of CD62P, a marker of platelet-monocyte 
heterotypic aggregates19 intermediate monocytes (Figure 2C). Whereas, in non-classical monocytes we 
observed a marked upregulation of the integrin CD49d (Figure 2D).  
 
 Several studies found that patients with COVID-19 pneumonia may also develop secondary 
bacterial infections27, 28. Thus, we next evaluated whether phagocytes from COVID-19 patients displayed 
altered phagocytic function. We evaluated the ability of peripheral blood phagocytes to uptake and kill 
Staphylococcus aureus as an exemplar bacterium of clinical relevance using bacterial particles labelled with 
a pH-sensitive fluorophore to monitor uptake and phagolysosome acidification, a key step in bacterial 
killing. This analysis demonstrated a significant downregulation in fluorescence levels in neutrophils, 
intermediate monocytes and non-classical monocytes from COVID-19 patients incubated with 
fluorescently labelled S. aureus (Figure 2E).  
 
 To evaluate whether the variations in SPM concentrations observed in COVID-19 patients were 
linked to changes in peripheral blood phagocyte activation status and function, we next conducted a 
correlation analysis (Figure 2F). This analysis demonstrated that arachidonic acid (AA)-derived mediator 
levels, such as those of Leukotriene (LT)B4, and LTE4, were generally positively correlated with activation 
marker expression on neutrophils, while n-3 DPA and DHA-derived mediators such as MCTR3, PCTR3, 
and RvT1 were negatively correlated with expression of activation markers on all three monocytes subsets. 
MCTR3 and PCTR3 were also significantly negatively correlated with CD54 (ICAM-1) and CD142 (Tissue 
factor) expression on non-classical monocytes, while RvT1 was negatively correlated with expression of 
integrin CD11b on classical and non-classical monocytes (Figure 2F). Plasma SPM concentrations were 
also linked with the ability of different phagocyte subsets to uptake bacteria. Here, we observed a significant 
positive correlation between plasma PD1, RvT1, RvE3 and 10S, 17S-diHDPA and the ability of neutrophils 
and monocytes to uptake S. aureus (Figure 2G). Taken together, these findings suggest that changes in SPM 
pathways are linked with an alteration in phagocyte activation status and function in COVID-19 patients.   
 
Downregulation of SPM in patients with severe COVID-19 pneumonia. 
 
We next investigated whether plasma LM concentrations differed with increasing disease severity 
in COVID-19 patients. For this purpose, we assessed plasma LM concentration in hospitalized patients with 
mild disease and compared them with those with severe disease based on their WHO Ordinal Scale of 
COVID-19 Disease Severity at time of sample collection. Using PLS-DA we found a marked shift in plasma 
LM concentrations in patients with a WHO scale of 3 or 4 (WHO 3-4), which indicates hospitalised patients 
with mild disease symptoms, when compared to those with a WHO scale of 5 (WHO 5), indicative of more 
severe pneumonia requiring non-invasive ventilation or high-flow oxygen (see Supplemental Table III for 
clinical characteristics). This shift in plasma LM profiles was due to an overall downregulation in DHA-
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upregulation of AA-derived LM, including the potent leukocyte chemoattractant LTB4 and LTE4, the 
downstream product of the pro-inflammatory smooth muscle-contractants LTC4 and LTD4 (Figure 3A and 
Supplemental Table IV).  
 
 To investigate the impact of disease severity on LM profiles in more detail, we evaluated LM 
profiles in patients with mild (WHO 3-4) and severe disease (WHO 5) according to their disease trajectory. 
Here, we separated patients based on whether their symptoms were improving or stable versus those that 
were either clinically deteriorating at time of sample collection or would ultimately succumb to the disease 
(referred to as deteriorating; Figure 3B-C, Supplemental Tables III, VII, VIII). PLS-DA demonstrated a 
shift in LM profiles between clinically improving/stable patients compared to deteriorating patients in 
patients with mild disease (Figure 3B). Notably, this distinction in LM profiles was observed to be even 
more pronounced in patients with severe disease (Figure 3C). For patients with mild disease, differences 
between improving/stable and deteriorating groups were primarily linked with higher concentrations of 
both SPM (i.e. RvD2, PCTR2, RvT2, RvT3, and RvD5n-3 DPA) and leukotrienes (i.e. LTB4 and LTD4) in 
patients that were clinically deteriorating (Figure 3B). On the other hand, differences between these two 
groups in patients with severe disease were primarily driven by higher levels of pro-resolving 15-epi-LXA4, 
RvD6, LXA4 and RvT1 in patients that were clinically improving or stable (Figure 3C).  
 
To explore the mechanisms underlying the altered SPM production in severe COVID-19 patients, 
we analysed the biosynthetic pathways of mediators with a VIP score >1 in the PLS-DA (shown in Figure 
3A). This analysis identified a downregulation in the levels of DHA and EPA-derived ALOX5-ALOX15 
interaction products, including RvD4 and RvE4. A reduction that was coupled with an increase in LXA4 
and LXB4 concentrations, the AA-derived products from these enzymes, in patients at WHO scale 5 
(Supplemental Figure I-B).  We also observed a decrease in peptide-lipid conjugated SPM (PCTR3 and 
MCTR3), suggesting that there was a reduction in activity of either the initiating ALOX enzymes in each 
of these pathways (ALOX15 or ALOX12, respectively) or their shared downstream biosynthetic enzymes. 
Notably, these downstream biosynthetic enzymes also produce cystenyl-leukotrienes such as LTE4, which 
was increased in patients with severe disease, suggesting a shift in the activity of these enzymes towards 
the formation of pro-inflammatory mediators (Supplemental Figure I-B).  
 
We next assessed the expression of SPM biosynthetic enzymes in circulating phagocytes. A trend 
for reduced expression of all enzymes under analysis with increased disease severity could be observed 
across all four phagocyte subsets, which reached statistical significance for ALOX5 and ALOX15B in 
neutrophils, COX-2 and ALOX5 in classical monocytes, and ALOX5 in non-classical monocytes (Figure 
3D-G). These results suggest that the differential regulation of SPM production observed in plasma from 
severe patients was in part linked with a downregulation of SPM biosynthetic enzyme expression in 
circulating phagocytes.  
 
We next evaluated whether SPM receptor expression was also altered with increased disease 
severity. Here, we found reduced expression of multiple SPM receptors on circulating phagocytes from 
severe COVID-19 patients. This included a significant downregulation of GPR18 on neutrophils, classical 
monocytes, and non-classical monocytes, as well as reduced expression of ChemR23, the receptor for RvE1 
and RvE2, on classical and intermediate monocytes. We also observed a significant downregulation in 
GPR32 on intermediate and non-classical monocytes, and a decrease in GPR101 on classical monocytes in 
patients with severe disease (Figure 3H-K). Together, these findings suggest that resolution pathways 
become dysregulated in COVID-19 patients with severe disease.  
 
Altered resolution pathways persist after resolution of COVID-19 clinical symptoms. 
 
Having observed a marked shift in LM profiles from patients with active COVID-19 pneumonia, 
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clinical symptoms (referred to as post-COVID-19). We collected peripheral blood from post-COVID-19 
volunteers between 12-25 days after the resolution of clinical symptoms (n=8) and compared their plasma 
LM profiles with those obtained from healthy volunteers with no clinical suggestion of COVID-19 infection 
(n=12; see Supplemental Table I for demographics). PLS-DA demonstrated that LM profiles obtained from 
post-COVID-19 volunteers were markedly different from those obtained from healthy volunteers (Figure 
4A and Supplemental Table II). This separation was primarily driven by differential regulation of 14 
mediators that included both pro-inflammatory eicosanoids, such as prostaglandin (PG)E2, PGF2α, and 
LTE4, and SPM, RvD1, RvD2 and RvT2 (Figure 4A).  
 
Examination of LM biosynthetic pathways indicated an upregulation of COX activity in post-
COVID-19 volunteers, as indicated by an increase in both pro-inflammatory (i.e. PGD2, PGE2 and PGF2a) 
and pro-resolving (RvT2) COX-derived products in these volunteers. We also found an overall increase in 
ALOX5-ALOX15 interaction products, including RvD1 and RvD2, and an increase in the ALOX5 products 
5S, 12S-diHETE and LTE4 in post-COVID-19 volunteers when compared with healthy volunteers 
(Supplemental Figure II-A). Intriguingly, expression of these biosynthetic enzymes in circulating 
phagocytes form post-COVID-19 patients was essentially the same as that observed in healthy volunteers 
(Supplemental Figure II-C-F). Thus, these results suggest that the alterations in resolution pathways 
observed in COVID-19 patients can persist even after the subsidence of clinical symptoms, and might arise 
from changes in activity of the LM biosynthetic enzymes. 
 
Changes in peripheral blood phagocyte activation status partially persist after the resolution of COVID-
19 clinical symptoms. 
 
We next assessed whether the observed changes in SPM pathways were linked with changes in 
peripheral blood phagocyte activation status and function in post-COVID-19 volunteers. Flow cytometric 
analysis demonstrated that post-COVID-19 neutrophils and classical monocytes displayed an activated 
phenotype as observed by marked shifts in the clusters representing these cells versus the clusters 
representing cells from healthy volunteers. This separation was primarily linked with an upregulation in 
CD11b on these cells (Figure 4B-C), an observation also previously made with cells from COVID-19 
pneumonia patients (Figure 2A-D). Conversely, the activation status of intermediate and non-classical 
monocyte from post-COVID-19 volunteers was not markedly different from healthy volunteer cells (Figure 
4D-E). Comparison of phagocytic ability of cells isolated from post-COVID-19 volunteers demonstrated 
that phagocytes from these volunteers displayed an essentially similar ability to uptake fluorescently 
labelled S. aureus when compared with healthy volunteers (Supplemental Figure II-B). We also did not 
observe marked differences in SPM receptor expression on circulating phagocytes from post-COVD-19 
volunteers when compared with healthy volunteers (Supplemental Figure II-G-J).  
 
 We next evaluated whether changes in phagocyte activation observed in post-COVID-19 
volunteers were correlated with the observed changes in peripheral blood SPM concentrations (Figure 4F). 
Here we found that neutrophil and monocyte expression of the platelet-leukocyte heterotypic aggregate 
marker CD41 and integrin CD11b positively correlated with a number of AA-derived leukotrienes and 
prostaglandins, while the SPM 15-epi-LXB4, 17R-RvD3, and MaR1 negatively correlated with CD62P, 
another marker of leukocyte-platelet aggregates (Figure 4F). Taken together, these findings indicate that 
alterations in phagocyte activation status and peripheral LM profiles persist after the resolution of clinical 
symptoms in SARS-CoV-2 infected individuals.  
 
Dexamethasone upregulates peripheral blood SPM concentrations in COVID-19 patients. 
 
Recent studies demonstrate that dexamethasone upregulates SPM formation in experimental 
allergic inflammation29. Therefore, we questioned whether this corticosteroid also regulated SPM formation 
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without 6mg/day of dexamethasone (see Supplemental Table V for patient information). Analysis of plamsa 
LM profiles using PLS-DA demonstrated a distinct clustering of the groups representing patients that 
received dexamethasone (COVID-19+Dex) versus those that did not (COVID-19; Figure 5A,B and 
Supplemental Table VI). This shift in plasma lipid mediator profiles was linked with an overall 
downregulation in plasma pro-inflammatory eicosanoid concentrations and an upregulation of plasma SPM 
concentrations (Figure 5C). 
 
Dexamethasone is known to regulate SPM enzyme expression in experimental settings30. We 
therefore evaluated whether the expression of SPM enzymes in circulating phagocytes was affected by 
dexamethasone treatment. Flow cytometric evaluation demonstrated a significant upregulation of ALOX15 
and ALOX15B in all phagocyte subsets, as well as ALOX12 in classical and intermediate monocytes of 
COVID-19 patients treated with dexamethasone (Figure 5D-G). These findings suggest that dexamethasone 
increases peripheral blood SPM concentration in COVID-19 patients via the upregulation of SPM 
biosynthetic enzymes in peripheral blood phagocytes. 
 
We next explored whether dexamethasone also regulated the expression of SPM receptors on 
circulating phagocytes. Flow cytometric analysis demonstrated that while expression of ALX/FPR2 (the 
receptor for LXA4, RvD1, RvD3 and their aspirin-triggered epimers) was significantly downregulated on 
all four phagocyte subsets, the expression of GPR18 was upregulated on these cells (Figure 5H-K). 
Moreover, GPR37 was downregulated on neutrophils and non-classical monocytes whilst it was 
upregulated on classical and intermediate monocytes (Figure 5H-K). Together these findings demonstrate 
that in addition to upregulating plasma SPM concentrations, dexamethasone also regulates SPM receptor 
expression on circulating phagocytes from COVID-19 patients.  
 
SPM rectify peripheral blood phagocyte responses. 
 
SPM potently regulate phagocyte activation status as well as their ability to uptake and kill 
bacteria13, 21, 24, 26, 31, 32. Having observed that dexamethasone upregulated plasma SPM concentrations we 
next evaluated the translational potential of these findings by testing the pharmacological properties of 
specific SPM in regulating the observed alterations in peripheral blood phagocytes. For this purpose, we 
focused on MCTR3, PCTR3, 17R-RvD3, and RvD2, given that plasma concentrations of MCTR3 and 
PCTR3 were found to correlate with phagocyte activation in COVID-19 patients and their levels were 
decreased in patients with severe disease. Whereas the receptors for 17R-RvD3 (GPR32), and RvD2 
(GPR18) were differentially regulated on phagocytes from these patients. Here we found that each SPM 
tested displayed characteristic regulatory activities on the four phagocyte subsets (Figure 6). While these 
mediators did not significantly alter expression of activation markers on neutrophils (Figure 6A), MCTR3 
treatment significantly decreased CD54, while PCTR3 downregulated CD49d expression on classical 
monocytes (Figure 6B). MCTR3 also decreased CD11b expression on non-classical monocytes (Figure 
6D). Recent studies found that expression of the coagulation-initiating CD142 is upregulated on circulating 
monocytes from COVID-19 patients, an increase that was linked with enhanced disease severity and 
mortality33. Incubation of monocytes with all four SPM tested led to an overall downregulation of CD142, 
reaching statistical significance for RvD2 treatment of non-classical monocytes (Figure 6B-D).  
 
Evaluation of the ability of MCTR3, PCTR3, 17R-RvD3, and RvD2 to regulate phagocyte 
responses based on disease severity (i.e. WHO ordinal scale), demonstrated a trend towards upregulation 
of CD162 on neutrophils from COVID-19 patients with milder disease. Whereas, these SPM did not 
regulate neutrophil activation markers on cells from patients with more severe disease (WHO scale 5; 
Supplemental Figure III-A). The same outcome emerged when monocytes were analysed, with SPM being 
more effective on classical and intermediate monocytes of WHO scale 3-4 patients (Supplemental Figure 
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regulation of activation marker expression appeared to be higher in cells from patients with severe disease 
(Supplemental Figure III-D).    
 
 We next evaluated whether SPM rescued the defect in S. aureus phagocytosis observed in 
peripheral blood leukocytes isolated from COVID-19 patients. Incubation of all four SPM with peripheral 
blood neutrophils led to an increase in phagocytosis by neutrophils, which reached statistical significance 
for PCTR3, 17R-RvD3, and RvD2 at 1nM (Figure 6E). We observed increases in S. aureus phagocytosis 
by peripheral blood monocytes when these cells were incubated with 1nM of either MCTR3 or PCTR3 
(Figure 6F). These mediators also significantly increased phagocytosis of Streptococcus pneumoniae, 
another clinically relevant bacterium in COVID-1934, by peripheral blood neutrophils and monocytes from 
COVID-19 patients, respectively (Figure 6G-H).  
 
SPM reprogram monocyte-derived macrophages from COVID-19 patients.  
 
Monocyte-derived macrophages are linked with onset, progression and resolution of both acute and 
chronic inflammation4, 13, 35. Furthermore, macrophage responses in COVID-19 patients are dysregulated, 
with these cells displaying an inflammatory phenotype that is linked with increased tissue inflammation 
and damage12. Having found that SPM regulate both monocyte activation and function, we next assessed 
whether these protective activities extended to monocyte-derived macrophages. For this purpose, we 
incubated monocytes isolated from peripheral blood of COVID-19 patients with SPM, differentiated them 
to macrophages using published protocols23, and assessed the expression of macrophage phenotypic 
markers using flow cytometry. Here we found that MCTR3, PCTR3, and 17R-RvD3 significantly 
downregulated CD32 and CD80 expression, whereas PCTR3 downregulated CD206 expression and 17R-
RvD3 downregulated Arginase (Arg)-1 and MerTK expression. Notably, all four SPM tested significantly 
downregulated the expression of CD142 (Figure 7A). Furthermore, the activity of these SPM was found to 
be comparable in patients with mild and severe disease (Supplemental Figure IV).  
 
 The excessive production of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6 and 
tumor necrosis factor (TNF)-α, is one of the hallmarks of severe COVID-199. Macrophage-derived 
cytokines play a central role in the propagation of tissue inflammation. Thus, we next evaluated whether 
SPM regulated cytokine production in monocyte-derived macrophages. Incubation of these cells with 
S100A8/A9 dimer, a potent pro-inflammatory signalling molecule that is abundant in inflamed tissues from 
COVID-19 patients8, 36, 37, upregulated the expression of interferon (IFN)-α, IL-1β, IL-6, IL-10 and TNF-α 
(Figure 7B-F). Incubating macrophages with MCTR3, PCTR3, 17R-RvD3 or RvD2 led to a significant 
decrease in the expression of S100A8/A9-induced IFN-α, IL-1β, and IL-6 expression, while MCTR3, 
PCTR3 and RvD2 also significantly decreased expression of IL-10 and TNF-α (Figure 7B-F). Of note, 
assessment of cytokine expression when separating COVID-19 patients by disease severity based on WHO 
ordinal scale demonstrated that all four SPM were equally effective at reducing expression of these 
cytokines in cells from both patient groups (Supplemental Figure V).  
 
 We next assessed whether SPM regulated phagocytic responses in these cells. Incubation of 
monocyte-derived macrophages with MCTR3, PCTR3, or 17R-RvD3 increased their ability to clear the 
Gram-positive bacteria S. aureus and S. pneumoniae in a concentration-dependent manner (Figure 7G-H). 
Given that secondary infections by fungi from the Aspergillus genus are also common in COVID-19 
patients38 we next tested whether these SPM also regulated the clearance of fungi. Here we found that 
MCTR3, PCTR3 and 17R-RvD3 dose-dependently increased uptake of fluorescently labelled zymosan, a 
fungal cell wall component (Figure 7I). Notably, while PCTR3 and 17R-RvD3 increased phagocytosis of 
S. aureus, S. pneumoniae and zymosan particles to a similar extent in cells from patients with mild disease 
when compared to those with severe disease, MCTR3 displayed greater activity with cells from patients 
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Since the extensive and unresolved inflammation observed in the lungs of COVID-19 patients gives 
rise to widespread tissue damage and apoptosis, we next assessed the ability of SPM to enhance the 
clearance of apoptotic cells (a process termed efferocytosis). Here, we found that PCTR3 increased 
efferocytosis of apoptotic cells by monocyte-derived macrophages from COVID-19 patients in a 
concentration-dependent manner (Figure 7J). Together these findings demonstrate that SPM alter the 






Our study presents evidence that selective determinants of pro-resolving pathways are present in 
the blood of patients with COVID-19 pneumonia and suggests that their dysregulation, or improper 
engagement, may contribute to disease propagation. In peripheral blood from these patients, we observed 
an upregulation of SPM concentrations and expression of pro-resolving receptors on circulating phagocytes 
when compared with healthy volunteers, which became dysregulated with increasing disease severity. 
These changes were linked with altered neutrophil and monocyte activation status and function when 
compared to phagocytes from healthy volunteers. Treatment of COVID-19 patients with dexamethasone 
upregulated both peripheral blood SPM concentrations and the expression of their biosynthetic enzymes, 
while incubation of peripheral blood phagocytes with SPM modulated both their activation status and 
ability to uptake bacteria. In addition, SPM potently tempered monocyte-derived macrophage responses, 
downregulating the expression of pro-inflammatory cytokines and upregulating their ability to clear 
pathogenic microbes and apoptotic cells. 
 
Phagocytes form the first line of defence against invading pathogens39-41. The behaviour of these 
cells is regulated by environmental cues that include soluble mediators such as cytokines and LM. Mounting 
evidence demonstrates that phagocyte behaviour becomes dysregulated in COVID-19 pneumonia patients 
with severe disease, contributing to uncontrolled systemic inflammation with ensuing organ damage7, 33, 42-
44. Furthermore, these disrupted phagocyte responses are linked with an increased susceptibility to 
secondary infections27, 28. In the present study, we observed that overall lipid mediator concentrations are 
upregulated in plasma from COVID-19 pneumonia patients. This concomitant increase in both pro-
inflammatory and pro-resolving mediators is a feature of several inflammatory conditions, including sepsis 
and acute respiratory distress syndrome18, and reflects the activation of counter-regulatory mechanisms by 
the host as an attempt to control unabated inflammation. Of note, Schwartz and colleagues reported that an 
increase in peripheral blood lipid mediator production is retained in serum from COVID-19 pneumonia 
patients45. The upregulation of SPM in both plasma and serum, together with an increase in the expression 
of SPM enzymes in peripheral blood monocyte subsets supports the hypothesis that activation of these cells 
is at least in part responsible for the observed increases in the concentrations of these molecules. Notably, 
plasma concentrations of SPM were decreased in those patients with more severe disease suggesting that 
inability of the host to upregulate these molecules leads to disease propagation. This hypothesis is further 
supported by the observation that in patients treated with dexamethasone, which has been shown to decrease 
disease severity and mortality in patients with severe COVID-196, we observed increased plasma SPM 
concentrations as well as SPM biosynthetic enzyme expression in circulating phagocytes.  
 
 Recent studies demonstrate that the increased platelet-leukocytes heterotypic aggregates found in 
COVID-19 patients are linked with an upregulation of CD142 on monocytes33. CD142 initiates the extrinsic 
coagulation cascade, is fully functional when expressed on cell surfaces, and increased CD142 expression 
is linked with a state of hypercoagulability and elevated disease severity in patients with COVID-19 
pneumonia33. Studies investigating the expression of CD142 indicate that the expression of this protein is 
regulated by both pro-inflammatory cytokines, such as IL-610, and pro-inflammatory mediators such as 
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three monocyte subsets as well as on monocyte-derived macrophages. The regulation of this molecule by 
SPM was also observed to be comparable between cells from hospitalized patients with mild and severe 
disease. These results suggest that in addition to regulating leukocyte recruitment and function, SPM may 
also contribute to reducing the hypercoagulable state observed in COVID-19 patients by downregulating 
the expression of CD142 on circulating and tissue-resident phagocytes. 
 
 During inflammation, monocytes are recruited into inflamed tissues where they differentiate to 
monocyte-derived macrophages that either contribute to the propagation of tissue inflammation or promote 
its resolution and tissue repair to facilitate the re-establishment of tissue function. Studies in COVID-19 
patients as well as in non-human primates demonstrate a marked increase in monocyte-derived 
macrophages numbers in various tissues, including lung, intestine, kidney, and liver7, 42, 43. These cells can 
contribute to the disseminated inflammatory status observed in COVID-19 patients via the production of 
both inflammatory cytokines such as IL-6, TNF-α and IFNs, as well as immunosuppressive agents such as 
IL-1011, 43. In the present study, we found that SPM potently downregulated the production of several 
inflammatory cytokines by monocyte-derived macrophages from COVID-19 patients. Intriguingly, Type I 
interferons and PGE2 downregulate bacterial phagocytosis by alveolar macrophages48, 49, suggesting that 
the decreased bacterial phagocytosis by COVID-19 patient-derived phagocytes might be due to elevated 
levels of these pro-inflammatory molecules counteracting endogenous SPM signalling. Consistent with this 
hypothesis, incubation of patient-derived monocyte-derived macrophages with SPM decreased IFN-α 
expression and increased their ability to uptake bacteria. Reduced inflammatory cytokine expression was 
also linked with a downregulation in the expression of phenotypic markers, including CD80 and CD206, 
which were recently found to be upregulated on monocytes from COVID-19 patients that express higher 
levels of pro-inflammatory cytokines44.  
 
 At epithelial surfaces, monocyte-derived macrophages play a central role in the clearance of 
pathogens. Several studies found that COVID-19 patients may also develop secondary bacterial or fungal 
infections27, 28. Here we found that MCTR3, PCTR3 and 17R-RvD3 significantly upregulated the uptake 
and killing of both bacteria and fungi by macrophages, an activity that was comparable between cells from 
patients with mild and severe disease. Taken together, the present findings highlight the potential 
pharmacological utility of SPM in regulating COVID-19-related immune cell responses. Such SPM-based 
therapeutics could either involve the use of SPM analogues/mimetics or the enhancement of endogenous 
SPM production through the administration of SPM substrates and precursors. Of note, we recently found 
that this latter approach enhances circulating SPM levels in healthy individuals and patients with peripheral 
artery disease, while it tempered phagocyte phenotype and function50, 51. 
 
The strengths of the present study are that it evaluates the correlation between changes in plasma 
SPM and changes in phagocyte functions in COVID-19 patients. Furthermore, it interrogates the potential 
pharmacological utility of SPM in rectifying altered phagocyte functions. There are also some limitations 
that should be considered when evaluating the present findings. First, we were unable to recruit individuals 
suffering from acute COVID-19 that did not require hospitalization (i.e. WHO scale 1-2). Nor were we able 
to obtain serial samples from the same patient over a period of time. Such patient groups and samples could 
provide further insight into when and how changes in LM profiles occur during COVID-19 disease 
progression. Additionally, our study was not sufficiently powered to explore potential interactions between 
COVID-19 and specific comorbidities known to affect LM concentrations in plasma. Notably, comparisons 
of LM concentrations in COVID-19 patients separated by disease severity (Figure 3) or dexamethasone 
treatment status (Figure 5) showed that there were no marked differences in the co-morbidities between 
these groups (Supplemental Tables III & V). Finally, future studies will be needed to establish the 
mechanisms that govern the observed changes in SPM biosynthesis. Here, we measured protein expression 
of key SPM biosynthetic enzymes as one aspect that defines their activity and therefore SPM production. 
For some of our comparisons, the changes in enzyme expression were consistent with changes observed in 
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plasma SPM concentrations and enzyme expression in leukocytes from post-COVID-19 volunteers. This 
observation suggests that additional mechanisms, e.g. subcellular localization or post-translational 
modifications of the enzymes52, may contribute to the LM profiles obtained in plasma from post-COVID-
19 volunteers (Supplemental Figure II).  
 
 In summation, in the present study we provide evidence that the host immune response engages 
resolution mechanisms as an attempt to limit the over-shooting inflammatory response following SARS-
CoV-2 infection. However, these protective mechanisms appear to fail in patients with severe COVID-19 
pneumonia, leading to systemic inflammation and dysregulated circulating phagocyte responses, which in 
turn contribute to secondary organ damage. Such inadequate resolution is linked with the downregulation 
of SPM receptors on leukocytes. Nonetheless, these receptors remain functional and incubation of 
phagocytes from COVID-19 patients with MCTR3, PCTR3, 17R-RvD3 or RvD2 rectified many of the 
phagocyte responses investigated. Together these findings shed new light on the mechanisms contributing 
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FIGURE LEGENDS 
 
Figure 1: Upregulation of SPM pathways in COVID-19 patients. 
Peripheral blood was collected from COVID-19 patients or healthy volunteers and (A-B) plasma lipid 
mediators were identified and quantified using LC-MS/MS-based mediator profiling (n=38 COVID-19 
patients, n=12 healthy volunteers). (A) PLS-DA was performed on identified mediators. Top panel – Scores 
plot, shaded area represents 95% confidence interval (CI), R2 = coefficient-of-determination, p = p-value 
from Hotelling’s T-squared test, dM = Mahalanobis distance between groups. Bottom Panel – VIP scores 
plot. (B) Analysis highlighting mediators with VIP scores >1 in PLS-DA and their biosynthetic pathways. 
(C-J) Whole blood from healthy volunteers and COVID-19 patients was incubated with lineage-marker 
antibodies against neutrophils (CD16+) and monocyte subsets (classical CD14++CD16+, intermediate 
CD14++CD16++, non-classical CD14+CD16++) in combination with antibodies against (C-F) lipid mediator 
biosynthetic enzymes or (G-J) SPM receptors, and their expression was evaluated using flow cytometry. 
For (C-F), n=19 COVID-19 patients (for COX-2, ALOX15), n=12 COVID-19 patients (for ALOX5, 
ALOX12, ALOX15B) and n=7 Healthy volunteers. For (G-J), n=11 COVID-19 patients (except for GPR18 
and GPR37 where n=10) and n=8 Healthy volunteers (except for GPR18 where n=3 Healthy volunteers). 
Statistical differences between Healthy and COVID-19 groups were established using Mann-Whitney Test 
for each molecule and raw p-values are displayed. 
 
Figure 2: Upregulation of activation markers and downregulation of S. aureus phagocytosis in 
circulating phagocytes from COVID-19 patients.  
(A-D) PLS-DA scores plots with 95% CI and VIP scores for activation markers on circulating phagocytes 
from healthy volunteers (n=9) and COVID-19 patients (n=11) assessed by flow cytometry. (E) S. aureus 
phagocytosis by peripheral blood neutrophils and monocyte subsets from healthy volunteers (n=11) and 
COVID-19 patients (n=11) evaluated using flow cytometry. Statistical differences between Healthy and 
COVID-19 groups were established using Mann-Whitney Test for each cell type and raw p-values are 
displayed. (F-G) Circos plots of Pearson correlation coefficients between COVID-19 patient (n=11) plasma 
LM levels and (F) phagocyte activation markers or (G) bacterial phagocytosis. Connecting bands represent 
statistically significant correlations (p<0.05), with the width of the band being proportional to the strength 
of the correlation (range -0.66-0.83) and band colour representing positive (green) or negative (red) 
correlations.  
 
Figure 3: Disruption of SPM pathways with increased disease severity in COVID-19 patients.  
Peripheral blood was collected from COVID-19 patients with mild (WHO scale 3-4; WHO 3-4) or severe 
disease (WHO scale 5; WHO 5). (A-C) Plasma lipid mediators were identified and quantified using LC-
MS/MS based lipid mediator profiling and PLS-DA was performed on identified mediators for the indicated 
patient sub-groups. Top panel – Scores plot with 95% CI. Bottom Panel – VIP scores plot. For (A), n=25 
WHO 3-4 patients and n=13 WHO 5 patients; for (B), n=21 WHO 3-4 improving/stable patients and n=4 
WHO 3-4 deteriorating/death patients; for (C), n=6 WHO 5 improving/stable patients and n=7 WHO 5 
deteriorating/death patients. (D-K) Whole blood from COVID-19 patients was incubated with lineage-
marker antibodies for neutrophils and monocyte subsets in combination with antibodies against (D-G) lipid 
mediator biosynthetic enzymes or (H-K) SPM receptors and their expression was evaluated using flow 
cytometry. For (D-G), n=14 WHO 3-4 patients (for COX-2, ALOX15), n=8 WHO 3-4 patients (for 
ALOX5, ALOX12, ALOX15B), n=6 WHO 5 patients (for COX-2, ALOX15), n=6 WHO 5 patients (for 
ALOX5, ALOX12, ALOX15B). For (H-K), n=7 WHO 3-4 patients and n=4 WHO 5 patients (except for 
GPR37 where n=3 WHO 5 patients). Statistical differences between WHO 3-4 and WHO 5 COVID-19 
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Figure 4: SPM pathways remain dysregulated after the resolution of clinical symptoms in SARS-
CoV-2 infected patients.  
Peripheral blood was collected from volunteers after the resolution of COVID-19 clinical symptoms (post-
COVID-19) or healthy volunteers. (A) Plasma lipid mediators were identified and quantified using LC-
MS/MS based lipid mediator profiling and PLS-DA was performed on identified mediators (n=12 healthy 
volunteers, n=8 post-COVID-19 volunteers). Top panel – Scores plot with 95% CI. Bottom Panel – VIP 
scores plot. (B-E) PLS-DA scores plots and VIP scores for activation markers on circulating phagocytes 
assessed by flow cytometry of peripheral blood from healthy (n=9) and post-COVID-19 (n=8) volunteers. 
(F) Circos plots of Pearson correlation coefficients between post-COVID-19 volunteer (n=8) plasma LM 
levels and circulating phagocyte activation markers. Connecting bands represent statistically significant 
correlations (p<0.05), with the width of the band being proportional to the strength of the correlation (range 
-0.93-0.93) and band colour representing positive (green) or negative (red) correlations. 
 
Figure 5: Dexamethasone upregulates plasma SPM in COVID-19 pneumonia patients.  
Peripheral blood was collected from COVID-19 patients treated with or without dexamethasone (Dex; 
6mg/day). (A-B) Plasma lipid mediators were identified and quantified using LC-MS/MS based lipid 
mediator profiling. PLS-DA was performed on identified mediators, (A) PLS-DA Scores Plot with 95% CI 
and (B) VIP scores plot. (C) Left panel - cumulative pro-inflammatory eicosanoids (PG, LT and TX); Right 
panel – cumulative SPM (Rv, PD, MaR, LX). Open squares indicate samples identified as statistical outliers 
using ROUT test (Q=0.2%) and statistical differences were established using Mann-Whitney Test (for 
which outliers were excluded). n=11 COVID-19 and n=27 COVID-19+Dex patients. (D-K) Blood was 
collected from COVID-19 or COVID-19+Dex patients and incubated with lineage-marker antibodies for 
neutrophils and monocyte subsets in combination with antibodies against (D-G) lipid mediator biosynthetic 
enzymes or (H-K) SPM receptors and their expression was evaluated using flow cytometry. For (D-G), 
n=4 COVID-19 patients and n=8 COVID-19+Dex patients (except for COX-2 where n=9 COVID-19+Dex 
patients). For (H-K), n=4 COVID-19 patients and n=7 COVID-19+Dex patients (except for GPR18 and 
GPR37 where n=6 COVID-19+Dex patients). Statistical differences between COVID-19 and COVID-
19+Dex patients were established using Mann-Whitney Test for each molecule and raw p-values are 
displayed.  
 
Figure 6: SPM regulate COVID-19 phagocyte activation and bacterial phagocytosis.  
Neutrophils and monocytes were isolated from peripheral blood of COVID-19 patients using density 
centrifugation. (A-D) Cells were incubated with 1nM of indicated SPM or vehicle for 60 minutes and 
expression of adhesion molecules was assessed using flow cytometry. Results are reported as percentage 
change from expression levels in cells incubated with vehicle only. Statistical differences were established 
using Wilcoxon Signed Rank test for each molecule and raw p-values are displayed. n=10 for neutrophils 
and n=17 for monocytes. (E-H) Neutrophils (E,G) and monocytes (F,H) were incubated with indicated 
SPM or vehicle for 15 minutes followed by fluorescently-labelled (E,F) S. aureus or (G,H) S pneumoniae 
and phagocytosis assessed in real-time using high-content imaging. Results are expressed as percent change 
from fluorescence levels recorded in cells incubated with vehicle only. For (E,G), n=10 COVID-19 patients 
(except RvD2 0.1nM where n=8). For (F), n=16 COVID-19 patients. For (H), n=12 COVID-19 patients. 
Statistical differences between SPM treatments and vehicle were established using Wilcoxon Signed Rank 
Test for each mediator and raw p-values are displayed. 
 
Figure 7: Regulation of COVID-19 monocyte-derived macrophage phenotype and function by SPM.  
(A-F) Monocytes were isolated from peripheral blood of COVID-19 patients and differentiated to 
monocyte-derived macrophages with GM-CSF in the presence of vehicle or 10nM of the indicated SPM. 
On day 7, (A) cells were lifted and the expression of the indicated phenotypic markers was assessed using 
flow cytometry (n=13 COVID-19 patients) or (B-F) cells were incubated with recombinant human 
S100A8/A9 dimer (1 µg/ml, 24 hours) and Brefeldin A (2 µg/ml, for final 18 hours) and the expression of 
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percentage change in expression from levels in cells incubated with vehicle only. Statistical differences 
between vehicle and SPM treatments were established using Kruskal-Wallis test with Dunn’s post-hoc 
correction. (G-I) Monocytes from COVID-19 patients were differentiated to monocyte-derived 
macrophages with GM-CSF, incubated with the indicated SPM (0.1 or 1 nM) or vehicle for 15 minutes 
followed by fluorescently-labelled (G) S. aureus, (H) S. pneumoniae, (I) zymosan, or (J) apoptotic cells. 
Results are reported as percentage change in uptake from levels in cells incubated with vehicle only. For 
(G-H), n=16 (for 0.1nM SPM) and n=15 (for 1nM SPM) COVID-19 patients. For (I), n=12 (for 0.1nM 
SPM) and n=11 (for 1nM SPM) COVID-19 patients. For (J), n=14 (for 0.1nM SPM) and n=8 (for 1nM 
SPM) COVID-19 patients. Statistical differences between SPM treatments and vehicle were established 













































 http://ahajournals.org by on July 14, 2021
 
DOI: 10.1161/CIRCRESAHA.121.319142   21 
NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Specialized pro-resolving mediators (SPM) are produced via enzymatic conversion of essential 
fatty acids and promote inflammatory resolution and tissue homeostasis. 
 
 Failure to resolve inflammation in a timely manner leads to chronic inflammation. 
 
 Severe cases of coronavirus disease 2019 (COVID-19) are characterized by a hyper-inflammatory 
state that is largely driven by innate immune cell dysfunction. 
 
What New Information Does This Article Contribute? 
 
 Circulating SPM concentrations were decreased in patients with severe disease, and correlated with 
the activation status and function of circulating phagocytes.  
 
 Perturbations in plasma SPM concentrations and phagocyte activation were retained after the 
resolution of mild disease, while treatment of severe COVID-19 patients with dexamethasone 
increased levels of circulating SPM as well as the expression of their biosynthetic enzymes. 
 
 Incubating phagocytes from COVID-19 patients with specific SPM rectified disease-associated 
perturbations in their phenotype and function. 
 
A subset of people infected with SARS-CoV-2 develop severe COVID-19 requiring hospitalization. These 
severe disease cases are characterized by a disseminated inflammatory response that can lead to 
cardiovascular complications and multi-organ failure. A better understanding of the mechanisms 
underpinning this dysregulated inflammatory response may provide novel therapeutic leads for the 
improved treatment of hospitalized patients. Given the known immuno-regulatory actions of SPM, we 
evaluated whether SPM pathways are altered in COVID-19 patients.  
 
The present study suggests that resolution mechanisms are engaged by the host in an attempt to resolve 
inflammation in the wake of SARS-CoV-2 infection. However, these protective mechanisms appear to fail 
in patients with severe COVID-19, leading to systemic inflammation and dysregulated circulating 
phagocyte responses. Inadequate resolution was found to be linked with downregulation of SPM 
biosynthetic enzymes and receptors on circulating leukocytes. Nonetheless, these receptors remain 
functional as incubation of phagocytes from COVID-19 patients with select SPM rectified many of the 
pathological phagocyte responses. Taken together, these findings shed new light on the mechanisms 
contributing to the disease propagation in COVID-19. Therefore, our study provides a basis for future 
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